自然抗氧化物质改善氧化应激,缓解性结肠炎:随机对照试验的元分析
Shuo Yuan1, Lingling Cai2, Man Su3
1Department of General Surgery, Beilun Branch of the First Affiliated Hospital of Zhejiang University, Ningbo, China.
Scientific reports
|November 29, 2025
概括
自然抗氧化剂补充改善了性结肠炎 (UC) 患者的氧化应激标志物和疾病活性. 虽然增强了抗氧化能力,但它没有显著影响生活质量,这表明它有可能作为UC的辅助疗法.
科学领域:
- 胃肠病学 胃肠病学
- 临床营养学 临床营养学
- 生物化学 生物化学
背景情况:
- 氧化应激是性结肠炎 (UC) 中粘膜损伤的主要原因.
- 抗氧化剂补充正在探索恢复氧化还原平衡,但临床证据是混合的.
- 天然抗氧化剂在治疗UC中的有效性需要进一步研究.
研究的目的:
- 评估天然抗氧化剂补充剂对UC患者氧化/抗氧化生物标志物的影响.
- 评估这些补充剂对临床结果的影响,包括疾病活性和生活质量.
- 综合UC抗氧化剂治疗随机对照试验 (RCT) 的证据.
主要方法:
- 进行了RCT的系统审查和元分析.
- 搜索的数据库包括到2025年7月的PubMed,Embase,Web of Science和Cochrane图书馆.
- 包括的研究比较了UC患者的口服抗氧化剂补充剂与安慰剂,分析了主要结果 (MDA,SOD,TAC,GPX) 和次要结果 (SIBDQ,SCCAI).
主要成果:
- 抗氧化剂补充剂显著降低了马隆迪阿尔海德 (MDA) 水平 (SMD=-1.09,P=0.001).
- 补充剂增加了超氧化物脱酶 (SOD),总抗氧化能力 (TAC) 和谷氨过氧化酶 (GPX) 水平 (P<0.05).
- 简单的临床结肠炎活动指数 (SCCAI) 评分显著下降 (SMD=-0.62,P=0.04),表明疾病活动有所改善,但简短IBD问卷 (SIBDQ) 评分显示没有显著变化 (P=0.13).
结论:
- 自然抗氧化物质有效增强抗氧化能力,改善UC患者的疾病活性.
- 补充改善与性结肠炎相关的氧化状态.
- 尽管疾病活性有所改善,但抗氧化剂补充并没有显著影响UC患者的生活质量,这表明其作为辅助疗法的作用.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
431
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
431
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
617
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
617
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
Peptic Ulcer Disease IV: Management
406
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
406
Inflammatory Bowel Disease IV: Pharmacological Management
450
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
450


